Sharon Worcester

2 weeks ago | medscape.com | Sharon Worcester

Immune checkpoint (IC) inhibitor drug holidays are safe in patients with metastatic melanoma who achieve an objective response (OR) during therapy, according to a study of more than 200 patients in Poland. More than 80% of patients maintained disease control without progression at 24 months after discontinuing immunotherapy. Those who had received IC inhibitor therapy for at least 24 months and achieved a complete response (CR) during therapy had the best outcomes, Anna M.

2 weeks ago | medscape.com | Sharon Worcester

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for the treatment of adults and children aged 12 years and older with certain types of colorectal cancer (CRC). Specifically, the combination is approved for those with metastatic microsatellite-high (MSI-H) or mismatch repair deficient (dMMR) CRC, adding to the list of other indications for the combination therapy.

2 weeks ago | mdedge.com | Sharon Worcester

FROM WCM-EADO 2025A noninvasive clinicopathologic and gene expression profiling (CP-GEP)–based tool, the Merlin assay, shows promise for identifying recurrence risks in patients with early-stage melanoma who do not undergo sentinel lymph node biopsy (SNLB).

2 weeks ago | medscape.com | Sharon Worcester

A noninvasive clinicopathologic and gene expression profiling (CP-GEP)–based tool, the Merlin assay, shows promise for identifying recurrence risks in patients with early-stage melanoma who do not undergo sentinel lymph node biopsy (SNLB). This was the conclusion of a retrospective analysis of a large cohort of patients with stage I/II disease, reported by Teresa Amaral, MD, PhD, at the 11th World Congress of Melanoma and 21st European Association of Dermato-Oncology Congress 2025.

3 weeks ago | medscape.com | Sharon Worcester

Pembrolizumab plus concurrent chemoradiotherapy shows ongoing antitumor activity after about 5 years of follow-up in patients with unresectable, locally advanced, stage III non–small cell lung cancer (NSCLC), according to final results from the phase 2 KEYNOTE-799 trial. The findings support continued investigation of this regimen, and phase 3 of the trial is in progress, first author Martin Reck, MD, PhD, reported at the European Lung Cancer Conference 2025.